Ludwig Enterprises Inc. (LUDG)
OTC PINK OTC PINK Primary Summary
Ludwig Enterprises Begins PCR Validation Test Process
Final step before the full launch of breast cancer screening program, Revealia™ SPARKS, NV / ACCESSWIRE / November 7, 2024 / Ludwig Enterprises, Inc. (OTC PINK:LUDG), a leading USA-based biotechnology company (the "Company"), has retained an independent lab in Florida that will conduct a third-party validation process for the Company's PCR (Polymerase Chain Reaction) breast cancer screening program, Revealia™. Once the validation protocols have been established and testing completed, Revealia™ will begin its nationwide launch.
Ludwig Enterprises Files Provisional Patent for Revolutionary Cancer Screening Algorithm, Plans 2024 Launch as Revealia(TM)
SPARKS, NV / ACCESSWIRE / October 24, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG), a leading USA-based biotechnology company, has filed a provisional patent for its breakthrough cancer detection method titled "mRNAs Differentially Expressed in Cancer." The company's latest innovation, which analyzes a six-mRNA gene combination, has demonstrated a significant increase in sensitivity and specificity for breast cancer detection, compared to previous methods.
CORRECTING AND REPLACING: Ludwig Enterprises Inc. Announces AI-Powered Cancer Screening Technology
This press release replaces the release issued today at 9:15am EDT. Revolutionary AI-driven cheek swab test poised to transform early cancer detection with continuously improving accuracy.
Ludwig Enterprises Inc. (LUDG) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Ludwig Enterprises Inc. ever had a stock split?
Ludwig Enterprises Inc. Profile
| Media Industry | Communication Services Sector | Jose Antonio Reyes CEO | OTC PINK Exchange | 54973P401 CUSIP |
| US Country | 5 Employees | 1 May 2009 Last Dividend | 16 May 2012 Last Split | - IPO Date |
Overview
Ludwig Enterprises, Inc. is a pioneering firm entrenched in the medical technology sector with a primary focus on holding. Established in 2006 and headquartered in Sparks, Nevada, the company distinguishes itself through its innovative approach in the biomedical field. Ludwig Enterprises is dedicated to advancing the healthcare industry by developing cutting-edge medical technologies, specifically messenger ribonucleic acid (mRNA) genetic testing kits. These products are meticulously designed to detect inflammatory genetic markers that are indicators of chronic diseases, marking a significant step forward in preventative healthcare and personalized medicine.
Products and Services
- mRNA Genetic Testing Kits:
At the core of Ludwig Enterprises' offerings are its mRNA genetic testing kits. These kits utilize advanced biotechnology to analyze genetic markers associated with inflammation, which is a common underlying factor in a wide array of chronic diseases. By focusing on mRNA, the technology provides insights into gene expression levels, offering a dynamic and precise approach to understanding an individual's genetic predisposition to various health conditions. This information can be pivotal for early detection, aiding in the development of tailored treatment plans and preventive measures for chronic diseases, thereby contributing to improved health outcomes and quality of life for patients.
